These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 21092476)

  • 1. [An open-label, multicentric clinical trial to evaluate the efficacy and impact on bone metabolism of recombinant human tumor necrosis factor-α receptor II IgG Fc fusion protein with methotrexate in active rheumatoid arthritis: 24-week clinical and radiographic results from ReABLE study].
    Wu QJ; Zhang ZL; Li ZB; Xu D; Li GT; Geng LF; Li MT; Wang Y; Zhu JJ; Hao YJ; Hui NL; Yang J; Cui XQ; Zhang XG; Zhao Y
    Zhonghua Yi Xue Za Zhi; 2010 Sep; 90(35):2481-5. PubMed ID: 21092476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.
    Weinblatt ME; Kremer JM; Bankhurst AD; Bulpitt KJ; Fleischmann RM; Fox RI; Jackson CG; Lange M; Burge DJ
    N Engl J Med; 1999 Jan; 340(4):253-9. PubMed ID: 9920948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations.
    Kremer JM; Weinblatt ME; Bankhurst AD; Bulpitt KJ; Fleischmann RM; Jackson CG; Atkins KM; Feng A; Burge DJ
    Arthritis Rheum; 2003 Jun; 48(6):1493-9. PubMed ID: 12794815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis.
    Bathon JM; Fleischmann RM; Van der Heijde D; Tesser JR; Peloso PM; Chon Y; White B
    J Rheumatol; 2006 Feb; 33(2):234-43. PubMed ID: 16465653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
    Maini RN; Breedveld FC; Kalden JR; Smolen JS; Davis D; Macfarlane JD; Antoni C; Leeb B; Elliott MJ; Woody JN; Schaible TF; Feldmann M
    Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter, randomized, double-blind clinical trial of combination therapy with Anbainuo, a novel recombinant human TNFRII:Fc fusion protein, plus methotrexate versus methotrexate alone or Anbainuo alone in Chinese patients with moderate to severe rheumatoid arthritis.
    Chen XX; Dai Q; Huang AB; Wu HX; Zhao DB; Li XF; Hu SX; Yang NP; Tao Y; Xu JH; Jiang LD; Bao CD
    Clin Rheumatol; 2013 Jan; 32(1):99-108. PubMed ID: 23053688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy.
    van der Heijde D; Burmester G; Melo-Gomes J; Codreanu C; Mola EM; Pedersen R; Freundlich B; Chang DJ;
    Ann Rheum Dis; 2008 Feb; 67(2):182-8. PubMed ID: 17728331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison study of a recombinant tumor necrosis factor receptor:Fc fusion protein (rhTNFR:Fc) and methotrexate in treatment of patients with active rheumatoid arthritis in China.
    Hu D; Bao C; Chen S; Gu J; Li Z; Sun L; Han X; Ni L
    Rheumatol Int; 2009 Jan; 29(3):297-303. PubMed ID: 18704426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacoeconomic evaluation for the treatment of rheumatoid arthritis].
    Liu B; Zeng XX
    Zhonghua Yi Xue Za Zhi; 2013 Mar; 93(11):841-4. PubMed ID: 23859391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, controlled trial of efficacy and safety of Anbainuo, a bio-similar etanercept, for moderate to severe rheumatoid arthritis inadequately responding to methotrexate.
    Chen XX; Li ZG; Wu HX; Zhao DB; Li XF; Xu JH; Tao Y; Yang NP; Hu SX; Huang AB; Jiang LD; Wang GC; Zhang X; Bao CD
    Clin Rheumatol; 2016 Sep; 35(9):2175-83. PubMed ID: 27184046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Cohen S; Hurd E; Cush J; Schiff M; Weinblatt ME; Moreland LW; Kremer J; Bear MB; Rich WJ; McCabe D
    Arthritis Rheum; 2002 Mar; 46(3):614-24. PubMed ID: 11920396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of recombinant human tumor necrosis factor receptor type II-Fc fusion protein antibody on cytokines and bone metabolism in patients with juvenile idiopathic arthritis].
    Li L; Zhang X; Cui Y; Lu YY; Wang SX; Dong GF; Shi YZ; Luo RQ; Lei YX
    Zhonghua Yi Xue Za Zhi; 2010 Aug; 90(31):2205-8. PubMed ID: 21029662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
    Kavanaugh A; St Clair EW; McCune WJ; Braakman T; Lipsky P
    J Rheumatol; 2000 Apr; 27(4):841-50. PubMed ID: 10782805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.
    Moreland LW; Baumgartner SW; Schiff MH; Tindall EA; Fleischmann RM; Weaver AL; Ettlinger RE; Cohen S; Koopman WJ; Mohler K; Widmer MB; Blosch CM
    N Engl J Med; 1997 Jul; 337(3):141-7. PubMed ID: 9219699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
    Seitz M; Zwicker M; Villiger PM
    J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy in Poland].
    Samborski W; Buczek J; Bednarek A; Lewandowicz J; Kucharz E
    Pol Merkur Lekarski; 2010 Dec; 29(174):365-8. PubMed ID: 21298986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis.
    Furst DE; Fleischmann R; Kopp E; Schiff M; Edwards C; Solinger A; Macri M;
    J Rheumatol; 2005 Dec; 32(12):2303-10. PubMed ID: 16331754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis.
    Moreland LW; Margolies G; Heck LW; Saway A; Blosch C; Hanna R; Koopman WJ
    J Rheumatol; 1996 Nov; 23(11):1849-55. PubMed ID: 8923355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etanercept biosimilar (recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial.
    Liu LF; Chen JS; Gu J; Xu JH; Jin HZ; Pang XW; Wang G; Yu C; Song ZQ; Guo ZP; Li W; Lai W; Cui PG; Chen M; Fang H; Lyu CZ; Li YZ; Sun Q; Xie HF; Liu XM; Gao XH; Shi YL; Zhao NQ; Zhang W; Zheng M
    Arch Dermatol Res; 2020 Aug; 312(6):437-445. PubMed ID: 31873772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
    Rau R; Schleusser B; Herborn G; Karger T
    J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.